StockNews.AISignal intelligence
Syndax Pharmaceuticals, Inc. · NASDAQ · Healthcare
Browse public SNDX signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Syndax (SNDX) saw a sharp premarket drop after MAXPIRE Phase 2 data showed axatilimab failed to meet the primary endpoint in idiopathic pulmonary fibrosis, specifically the annualized rate of decline in forced vital capacity. The setback casts doubt on the program’s near-term value and could influence Syndax’s financing options and potential partnering discussions in the coming months.
View signal analysisFDA approved SNDX's drug for blood cancer treatment. SNDX shares rose 3% in after-hours trading.
View signal analysisSNDX closed at $23.50, gaining 18.2% in four weeks. Analysts project a mean price target of $35.31, indicating 50.3% upside. Analyst agreement on earnings revisions supports potential for stock upside. Zacks Consensus Estimate raised by 2.1% over the last month. SNDX holds a Zacks Rank #2, indicating strong buy sentiment.
View signal analysis